Business Wire

Shippeo Tops 103% Annual Growth, Becomes World's Most Recommended Real-time Transportation Visibility Provider

13.10.2021 14:10:00 EEST | Business Wire | Press release

Share

Shippeo, a global leader and European specialist in real-time transportation visibility, announced today 103% year-on-year growth in subscription revenues and 181% net retention rate. The visibility solutions provider maintains the fastest growing customer base in Europe, having expanded its presence globally with the acquisition of several new high-profile customers currently being deployed in North America, Latin America, and APAC.

Since January, Shippeo has welcomed several new large international brands, including Coca-Cola HBC, one of the largest strategic bottling partners of The Coca-Cola Company; Nexans, a global player in energy transition; XPO Logistics, an American freight transportation company; and Woco Group, a global automotive component specialist, who supplies major OEMs.

A number of other category-leading brands have also chosen Shippeo’s real-time visibility solution, including Sappi, a leading producer of coated graphic paper, packaging and specialty papers; Conad, an Italian retail brand operating one of the largest supermarket chains in Italy; Fnac Darty Group, a French multinational electrical retailing company; Studio Moderna, an e-commerce company primarily operating across Central and Eastern Europe; and IDS, a Dutch 4PL logistics control tower specialist.

“Our very high net retention rate is a direct result of customers choosing to take fuller advantage of our expanding product portfolio, which now includes dock visibility and paperless visibility. Our ocean visibility has also become particularly popular as factors including Covid, the Suez blockage, and a global shortage of containers only intensifies the focus on the performance of this critical transport mode,” says Lucien Besse, COO of Shippeo.

“Shippeo has been recognized with a 98% recommendation rate on Gartner Peer Insights by our customers as at October 13, 2021*. I’m particularly proud of this achievement. Nothing is more important to us than delivering value to our customers and this is a fantastic result,” says Besse.

Shippeo’s team has expanded to over 230, with more than 90 new team members joining since January. Shippeo is on track to have more than doubled its staff year-on-year by the end of 2021. In addition, a number of senior profiles joined the company, including Nicolas Doucet, Strategic Alliance Director, previously at PTV Group; Guy-Pascal Bourlard, Head of Quality Assurance, previously at Amazon; Olivier Marcellin, Product Director, previously at Criteo; Marius Neuhäuser, Head of Solution Consulting, Alessandro De Martini, Business Development Director Italy, previously Country Manager at Transporeon and Bas Kramer, Business Development Director Benelux.

Furthermore, Shippeo is now expanding its operations into North America. As part of this strategic expansion, the company has welcomed Christopher Mazza as Senior Vice President, International Growth who will be responsible for leading the company’s activities in the region and growing Shippeo’s customer base. Christopher has extensive experience in the transportation and logistics industry, having participated in the creation of ClearMetal where he played an integral role in business development before joining project44 following the company's acquisition.

Recently the company announced new strategic partnerships with Savoye, a leading designer and integrator of complete supply chain solutions, and Tesisquare, a leading provider of supply chain execution applications. Shippeo has also partnered with Siemens DL, a leading IT provider in global supply chain management solutions.

The collaborations aim to make it easier for customers to overcome transport management challenges by leveraging deep TMS integrations, making it simple to take advantage of real-time visibility’s many benefits.

“We’re incredibly proud of the momentum we’re experiencing and the fact that we’ve maintained 0% customer churn throughout the year,” says Besse. “It’s really thanks to our extremely dedicated teams, our holistic customer-centric approach and a focus on the quality of our solution implementations, relationships and accelerated time to value for customers.”

Learn more

*https://www.gartner.com/reviews/market/real-time-transportation-visibility platforms/vendor/shippeo/product/shippeo-visibility-platform

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation.
Gartner research publications consist of the opinions of
Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Shippeo
Audrey Emanuel
audrey.emanuel@shippeo.com
+33 6 17 33 36 47

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye